A femto future?

Article

The act of collaboration is generally regarded positively. Uniting two parties that share a common interest usually yields achievements that could not have been possible if either party went at it alone, and so the whole becomes greater than the sum of the parts.

The act of collaboration is generally regarded positively. Uniting two parties that share a common interest usually yields achievements that could not have been possible if either party went at it alone, and so the whole becomes greater than the sum of the parts.

Certainly, this was the thinking behind Schwind and Bausch & Lomb’s recent strategic moves, which resulted in collaborations with established femtosecond laser manufacturers for the two firms. Both companies had already cemented their reputation in the laser refractive surgery market, although one key ingredient was missing from both: the technology that has created a big buzz around the ophthalmology community - the femtosecond laser. The all-LASIK solution that both Schwind and Bausch & Lomb are now able to offer is something that many surgeons and even patients are now requesting.

Despite its growing popularity, the jury is still out on whether femtosecond technology is in fact a must for all refractive surgeons. While many ophthalmologists think that femtosecond technology is the decade’s most significant technological breakthrough, there are those who remain at best undecided and, at the more extreme end of the spectrum, even downright cynical. Particularly in the practice of laser refractive surgery, is a femtosecond laser really such an improvement over a mechanical microkeratome? Some believe not.

Whether refractive surgeons have signed up to the femtosecond fan club or not, today’s refractive surgery practice needs to appear to be at the forefront of technology in order to keep pace in this hugely competitive market. Because of the strong marketing messages and effective advertising campaigns transmitted by some refractive clinics, particularly in the US and Europe, it seems that in order to be, or to be perceived to be, “at the forefront of innovation”, today’s refractive surgery practice needs to jump on the femtosecond bandwagon. Coupled with the expanding indications now being assessed for this technology, there is no way for the femtosecond technology market to go in the next few years other than up.

Best wishes,

Fedra PavlouEditorfpavlou@advanstar.com

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.